81336-70-1

Basic information

• Product Name: dichloromethylenebisphosphonic acid bis(tri-n-butylammonium) salt
• CAS NO: 81336-70-1
• Molecular Weight: 615.599
• Mol File: 81336-70-1.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: dichloromethylenebisphosphonic acid bis(tri-n-butylammonium) salt(CAS DataBase Reference)
• NIST Chemistry Reference: dichloromethylenebisphosphonic acid bis(tri-n-butylammonium) salt(81336-70-1)
• EPA Substance Registry System: dichloromethylenebisphosphonic acid bis(tri-n-butylammonium) salt(81336-70-1)

Safety Data

• Hazardous Substances Data: 81336-70-1(Hazardous Substances Data)

Upstream product

• 102-82-9 tributyl-amine 
• 10595-91-2 bisodium clodronate 

Downstream Products

• 1208347-12-9 C₁₉H₂₂Cl₂N₇O₁₁P₃ 

Relevant articles and documents

Synthesis and structure-activity relationship of uracil nucleotide derivatives towards the identification of human P2Y6 receptor antagonists

P2Y6 receptor (P2Y6-R) is involved in various physiological and pathophysiological events. With a view to set rules for the design of UDP-based reversible P2Y6-R antagonists as potential drugs, we established structure-activity relationship of UDP analogues, bearing modifications at the uracil ring, ribose moiety, and the phosphate chain. For instance, C5-phenyl- or 3-NMe-uridine-5′-α,β-methylene-diphosphonate, 16 and 23, or lack of 2′-OH, in 12-15, resulted in loss of both agonist and antagonist activity toward hP2Y6-R. However, uridylyl phosphosulfate, 19, selectively inhibited hP2Y6-R (IC50 112 μM) versus P2Y2/4-Rs. In summary, we have established a comprehensive SAR for hP2Y6-R ligands towards the development of hP2Y6-R antagonists.

Nucleotide mimics and their prodrugs

The present invention relates to nucleoside diphosphate mimics and nucleoside triphosphate mimics, which contain diphosphate or triphosphate moiety mimics and optionally sugar-modifications and/or base-modifications. The nucleotide mimics of the present invention, in a form of a pharmaceutically acceptable salt, a pharmaceutically acceptable prodrug, or a pharmaceutical formulation, are useful as antiviral, antimicrobial, and anticancer agents. The present invention provides a method for the treatment of viral infections, microbial infections, and proliferative disorders. The present invention also relates to pharmaceutical compositions comprising the compounds of the present invention optionally in combination with other pharmaceutically active agents.